A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...

Moderna's norovirus vaccine trial paused due to a rare neurological effect, Citadel's short position in GSK, bird flu response issues during Trump's term, WHO's call for alcohol warning labels, and ...

LANSING, Mich. (WILX) - Roughly one-tenth of the workforce at the Centers for Disease Control and Prevention are expected to ...

Earnings: Discover insights into revenue shifts, cost reductions, 2027 product goals, RSV market strategies, and its broader ...

Vaccine maker Moderna had no Valentine’s Day chocolates for investors when its financial results came out Friday. The company ...

In its fourth-quarter earnings report, Moderna’s revenue was down substantially from 2023. Separately, media reports reveal anticipated cuts to the company’s digital team.

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 ...

The slip-up hands an opportunity for mRNA vaccine rival Moderna to build a lead in the combined COVID-19/flu vaccine category. In June, Moderna said its candidate met its objectives in a phase 3 ...